Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of December 2025, with the specific transaction date being December 12, 2025. The report details a share repurchase executed as part of an existing buyback programme under a non-discretionary agreement with BNP Paribas SA.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and does not provide operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased: 230,000 ordinary shares.
- Price Range: Lowest price paid was 1,816.00 GBp; highest price paid was 1,837.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,827.59 GBp.
- Treasury Shares Held: 238,856,577 ordinary shares (post-transaction).
- Shares in Issue: 4,076,584,506 ordinary shares (excluding Treasury shares).
- Treasury Voting Rights: 5.86% of total voting rights.
Material Changes
Since the commencement of the current buyback programme on September 30, 2025, GSK has purchased a total of 13,391,733 ordinary shares. The transaction reported on December 12, 2025, represents the latest increment in this programme, increasing the total treasury holding to approximately 238.9 million shares.
Outlook, Risks, and Management Commentary
The company confirms that the purchased shares will be held as Treasury shares. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being detailed in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q3 Results for 2025. No specific new risks or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since September 30, 2025 (13,391,733 shares).
- Confirm the updated total of Treasury shares held (238,856,577) and the percentage of voting rights they represent (5.86%).
- Review the specific trading venues (XLON, CHIX, BATE) and transaction times to ensure compliance with market rules.
- Check the company's Annual Report on Form 20-F for 2024 and Q3 2025 results for the full context of risk factors mentioned in the cautionary statement.